The pathway to inflammation in asthma: the role of the DP2 receptor Source: International Congress 2019 – The journey towards personalized medicine in asthma: where are we now? Year: 2019
Selective versus non-selective endothelin receptor antagonists Source: Annual Congress 2005 - New treatments in pulmonary hypertension Year: 2005
Mas receptor antagonist inhibits the pro-resolutive effects of Angiotensin-(1-7) in an experimental model of asthma. Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019
Is there a link between long-term endothelial receptor antagonists therapy and carcinogenesis in PAH: A case series? Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Cysteinyl leukotriene receptor 1 gene variation and risk of asthma Source: Eur Respir J 2009; 33: 42-48 Year: 2009
The effects of formyl peptide receptor agonist on the asthma pathogenesis Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010
Homozygosity for the FCER2 gene is associated with an increased use of leukotriene receptor antagonists Source: International Congress 2017 – Insight into childhood asthma and paediatric pulmonology Year: 2017
Leukotriene C4 synthase polymorphism does not associate with clinical response to leukotriene receptor antagonists in persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
Interleukin-1R antagonist gene and pre-natal smoke exposure are associated with childhood asthma Source: Eur Respir J 2007; 29: 502-508 Year: 2007
Additional overall benefit to coexistent asthma and rhinitis symptoms control in patients treated with leukotriene receptor antagonist Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Long acting ß2 -agonist or leukotriene receptor antagonist in asthmatics at step 3 of BTS guidelines? Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II Year: 2007
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020
A novel receptor antagonist, c-027, inhibits airway contraction in human and murine models of allergen, independent of inflammatory mediator release Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
An association study between thromboxane A2 receptor gene T924C polymorphism and the severity of asthma in Chinese children Source: Eur Respir J 2001; 18: Suppl. 33, 451s Year: 2001
Expression and activity of bradykinin B2 receptor (B2R) in human airway fibroblast (HAFbs): a role in asthma remodeling Source: Eur Respir J 2006; 28: Suppl. 50, 748s Year: 2006
EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016